Trevi Therapeutics Inc. – Financial Overview and Market Context
Trevi Therapeutics Inc. (NASDAQ: TREV) is a U.S.-based pharmaceutical company headquartered in New Haven, Connecticut. The company focuses on the development of two clinical‑stage products: nalbuphine ER for chronic cough in patients with idiopathic pulmonary fibrosis and a levodopa‑induced dyskinesia therapy. Its operations are confined to the United States.
Market Performance (as of 24 Nov 2025)
- Closing price: US$11.36
- 52‑week high: US$12.30
- 52‑week low: US$2.36
- Market capitalization: US$1.46 billion
- Price‑earnings ratio: –30.82 (negative, reflecting pre‑revenue status)
Key Financial Indicators
| Indicator | Value |
|---|---|
| Asset Type | Company |
| Sector | Health Care |
| Primary Exchange | Nasdaq |
| Currency | USD |
The company’s negative P/E ratio is typical for a drug developer that has not yet generated revenue. Its stock price has shown volatility, reaching a low of US$2.36 in late 2024 before recovering to a peak of US$12.30 earlier in November 2025.
Recent Regulatory Activity
On 24 Nov 2025, several notices were issued by the National Stock Exchange of India (NSE) and Bombay Stock Exchange (BSE) concerning a special window for re‑lodgement of transfer requests for Blue Dart Express Limited. These documents are unrelated to Trevi Therapeutics and do not affect its operations or share price.
Implications for Investors
Investors considering Trevi Therapeutics should focus on the company’s clinical development pipeline and regulatory milestones rather than the unrelated exchange notices. The stock remains highly speculative, with its valuation driven by the potential commercial success of its two investigational therapies.
